Cisplatin

Generic Name
Cisplatin
Brand Names
Platinol
Drug Type
Small Molecule
Chemical Formula
Cl2H6N2Pt
CAS Number
15663-27-1
Unique Ingredient Identifier
Q20Q21Q62J
Background

Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication

For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions
Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)

First Posted Date
2021-08-30
Last Posted Date
2024-12-11
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
35
Registration Number
NCT05027633
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

First Posted Date
2021-08-25
Last Posted Date
2024-11-25
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
55
Registration Number
NCT05019716
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Los Angeles General Medical Center, Los Angeles, California, United States

🇺🇸

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

and more 2 locations

A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)

First Posted Date
2021-08-23
Last Posted Date
2024-12-27
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
72
Registration Number
NCT05017012
Locations
🇨🇱

James Lind Centro de Investigación del Cáncer ( Site 0102), Temuco, Araucania, Chile

🇨🇱

FALP-UIDO ( Site 0101), Santiago, Region M. De Santiago, Chile

🇿🇦

Cancercare Rondebosch Oncology-Clinical trials ( Site 0055), Rondebosch, Western Cape, South Africa

and more 19 locations

Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases

First Posted Date
2021-08-19
Last Posted Date
2024-08-19
Lead Sponsor
Fundación GECP
Target Recruit Count
71
Registration Number
NCT05012254
Locations
🇪🇸

Hospital Provincial de Castellón, Castelló de la Plana, Castellon, Spain

🇪🇸

Hospitalario Universitario A Coruña, A Coruña, La Coruña, Spain

🇪🇸

Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

and more 15 locations

Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC

First Posted Date
2021-08-18
Last Posted Date
2024-01-16
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
30
Registration Number
NCT05011487
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

First Posted Date
2021-08-16
Last Posted Date
2024-10-21
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
604
Registration Number
NCT05007106
Locations
🇺🇸

Memorial Sloan Kettering - Bergen ( Site 1025), Montvale, New Jersey, United States

🇺🇸

Memorial Sloan Kettering - Monmouth ( Site 1022), Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering - Basking Ridge ( Site 1023), Basking Ridge, New Jersey, United States

and more 70 locations

PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

First Posted Date
2021-08-16
Last Posted Date
2021-12-21
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
92
Registration Number
NCT05007145
Locations
🇨🇳

Fujian Cancer Hospital, Fuzhou, Fujian, China

🇨🇳

the Second Hospital of Longyan, Longyan, Fujian, China

🇨🇳

the First Hospital of Putian City, Putian, Fujian, China

and more 3 locations

AB122 Platform Study

First Posted Date
2021-08-11
Last Posted Date
2024-02-16
Lead Sponsor
Taiho Pharmaceutical Co., Ltd.
Target Recruit Count
715
Registration Number
NCT04999761
Locations
🇯🇵

A site selected by Taiho Pharmaceutical Co., Ltd., Wakayama, Japan

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

First Posted Date
2021-08-05
Last Posted Date
2024-11-20
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
60
Registration Number
NCT04991025
Locations
🇺🇸

Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities, Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

First Posted Date
2021-08-04
Last Posted Date
2023-09-26
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT04989283
Locations
🇺🇸

Community Medical Hospital, Missoula, Montana, United States

🇺🇸

The Mark H Zangmeister Center, Columbus, Ohio, United States

🇺🇸

Rush - Copley Medical Center, Aurora, Illinois, United States

and more 43 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy